Commerzbank Ag set a €66.00 ($73.33) price target on STADA Arzneimittel AG (ETR:SAZ) in a research note issued to investors on Saturday, May 20th. The firm currently has a neutral rating on the stock.
Shares of STADA Arzneimittel AG (SAZ) traded up 0.09% during trading on Friday, hitting €64.44. The stock had a trading volume of 143 shares. STADA Arzneimittel AG has a 1-year low of €40.50 and a 1-year high of €67.60. The firm has a 50 day moving average of €64.95 and a 200 day moving average of €56.49. The company has a market capitalization of €4.01 billion and a price-to-earnings ratio of 38.04.
WARNING: “STADA Arzneimittel AG (SAZ) Given a €66.00 Price Target at Commerzbank Ag” was originally reported by BBNS and is the sole property of of BBNS. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://baseballnewssource.com/markets/stada-arzneimittel-ag-saz-given-a-66-00-price-target-by-commerzbank-ag-analysts-updated-updated-updated/804294.html.
About STADA Arzneimittel AG
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products.
Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with our FREE daily email newsletter.